Chennai: The city-based Cephalosporin bulk drug major Orchid Chemicals and Pharmaceuticals today announced that Cephalexin, its flagship product manufactured in its Alathur bulk drug facility, has gone through the US Food and Drugs Administration (USFDA) audit successfully.

A formal communication from USFDA certifying the product is expected soon once due formalities are completed at their end.

Says Orchid managing director K Raghavendra Rao: “Coming at a time when Orchid is making significant investments in new USFDA-compliant plants and processes, and is strongly working towards an entry into regulated markets with a wide range of our Cephalosporin products, this is definitely going to provide us with a great impetus.”